Oral Therapeutic Composition for Dry Eye Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome and vitreous opacities, such as artificial tears and surgical procedures, provide only temporary relief and are not effective in addressing the underlying issues of tear film instability and ocular surface disease.
Innovation Solution
An orally administered composition comprising a mixture of water-soluble and water-insoluble antioxidants, essential fatty acids, glycoprotein complex, phospholipids, phytosterols, curcuminoids, and micronutrient cofactors like vitamin B6 and copper, which synergistically replenishes the tear film layers, reduces inflammation, and stabilizes the tear film.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If artificial tears are administered to treat dry eye syndrome, then temporary rehydration of the eyes is achieved, but relief is short-lived and frequent dosing is necessary
Solution Approach 1:
The patent applies preliminary action by administering oral supplements (omega-3 fatty acids, antioxidants, vitamins) before the actual tear production issue occurs. These supplements prepare the body's systems in advance to naturally produce better-quality tears and reduce inflammation, thereby extending the duration of relief and reducing the need for frequent artificial tear dosing.
Solution Approach 2:
The patent enables self-service by stimulating the body's own natural tear production mechanisms through oral supplementation. Instead of relying continuously on external artificial tears, the composition helps the patient's lacrimal glands and ocular surface cells regenerate and produce their own protective tear film, reducing dependence on frequent external interventions.
2Reliability
If artificial tears are used to treat dry eye syndrome, then temporary rehydration is achieved, but contra-indications and incompatibility with soft contact lenses occur
Solution Approach 1:
The patent enables self-service by stimulating the body's own natural tear production mechanisms through oral supplementation. Instead of relying continuously on external artificial tears, the composition helps the patient's lacrimal glands and ocular surface cells regenerate and produce their own protective tear film, reducing dependence on frequent external interventions.
3Reliability
If current medications are administered for xerophthalmia syndrome, then treatment is attempted, but only limited results are achieved
Solution Approach 1:
The patent applies composite materials by combining multiple active ingredients in a synergistic formulation: omega-3 fatty acids (for tear film stability and anti-inflammatory effects), antioxidants like vitamins C and E (for protecting ocular cells from oxidative damage), and other supportive nutrients. This multi-component composite approach addresses multiple aspects of dry eye pathophysiology simultaneously, achieving better clinical outcomes than single-agent medications.
Solution Approach 2:
The patent converts harmful oxidative stress and inflammation into beneficial effects by using antioxidants and anti-inflammatory omega-3 fatty acids to neutralize free radicals and reduce inflammatory mediators. The composition transforms the harmful oxidative environment that contributes to dry eye disease into a protective antioxidant-rich environment that promotes ocular surface healing and tear film stability.
Data Source
AI summary
A composition and method for treating dry-eye syndrome and symptoms of vitreous opacities in a host comprising the oral administration of a composition which contains a pharmacologically effective amount of essential fatty acids, polar phospholipids, vitamins, minerals and dietary supplements.